NCT00783341
Completed
Phase 1
An Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as 6-Day Continuous Infusions to Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 sites25 target enrollmentNovember 2008
Overview
- Phase
- Phase 1
- Intervention
- GAP-134
- Conditions
- Healthy Subjects
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Enrollment
- 25
- Primary Endpoint
- Safety as determined by reported adverse events, laboratory test results, and ECGs
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
GAP-134
Intervention: GAP-134
placebo
Intervention: placebo
Outcomes
Primary Outcomes
Safety as determined by reported adverse events, laboratory test results, and ECGs
Time Frame: 3 weeks
Secondary Outcomes
- Pharmacokinetic parameters(9 days)
Similar Trials
Completed
Phase 1
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) PatientsLeber Hereditary Optic NeuropathyNCT02064569GenSight Biologics19
Completed
Phase 1
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.GastroparesisNCT00733551GlaxoSmithKline31
Withdrawn
Phase 1
A Study of Single Ascending Doses of STAR-101 in Healthy ParticipantsHealthy VolunteersNCT04081597Acanthas Pharma Inc
Completed
Phase 1
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CChronic Hepatitis C InfectionGenotype 1NCT01194037HanAll BioPharma Co., Ltd.30
Completed
Phase 1
Safety Study of CN-105 Neuroprotective Peptide for Intracerebral HemorrhageIntracerebral Hemorrhage (ICH)NCT02670824AegisCN LLC48